Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, ...

What consumers searching for a natural GLP-1 supplement should know about Bioma GLP-1 Booster's Akkermansia muciniphila and ...

Conducting research is hard; confirming the results is, too. And artificial intelligence isn’t yet ready to help, a major new ...

Good morning, everyone, and welcome to Imunon's Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call. During to ...

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage ...

On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase ...

Analysis of billing codes before and after implementation of a care process for weight-focused visits revealed increased ...

The words on this page mean something because they are assembled in a particular order and follow the complex rules of ...

The first randomized controlled trial of an AI therapy chatbot found significant symptom reductions for depression and ...

A nephrologist and kidney stones expert, Dr David Goldfarb, presents 7 key highlights from the R.O.C.K. Society Annual Meeting 2026.

Introduction Diabetes distress is a common health problem among people living with type 2 diabetes (T2D), making it difficult to manage the condition. Though it remains a problem, limited attention ...